| Dapagliflozin group | Metformin group | P value |
---|---|---|---|
FMD (%) | |||
 FAS population | |||
  Baseline | 4.80 ± 1.86 (37) | 5.37 ± 2.95 (37) | 0.33 |
  Week 16 | 5.66 ± 2.12 (37) | 5.18 ± 2.09 (37) | 0.33 |
  Change | 0.85 ± 2.71 (37) | −0.19 ± 2.51 (37) | 0.09 |
  P value within group | 0.06 | 0.65 |  |
 Subpopulation: HbA1c at baseline <7.0% | |||
  Baseline | 4.72 ± 1.88 (24) | 4.88 ± 2.76 (20) | 0.83 |
  Week 16 | 5.47 ± 2.42 (24) | 5.33 ± 2.23 (20) | 0.85 |
  Change | 0.75 ± 2.82 (24) | 0.45 ± 2.48 (20) | 0.71 |
  P value within group | 0.21 | 0.43 |  |
 Subpopulation: HbA1c at baseline ≥7.0% | |||
  Baseline | 4.95 ± 1.91 (13) | 5.94 ± 3.14 (17) | 0.30 |
  Week 16 | 6.01 ± 1.43 (13) | 5.01 ± 1.96 (17) | 0.12 |
  Change | 1.05 ± 2.59 (13) | −0.94 ± 2.39 (17) | 0.041 |
  P value within group | 0.17 | 0.13 |  |